Hannah Linden, MD
Enriched profileClinical Director, Breast Cancer Program, Fred Hutch · Fred Hutchinson Cancer Center (Fred Hutch)
Hannah Linden is Clinical Director, Breast Cancer Program, Fred Hutch at Fred Hutchinson Cancer Center (Fred Hutch). OpenAlex indexes 229 publications with 5,542 citations (h-index 40); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 23 Oct 2026
Hannah M. Linden is Clinical Director, Breast Cancer Program, Fred Hutch at Fred Hutchinson Cancer Center (Fred Hutch). The public record shows 229 publications with 5,542 citations (h-index 40), centered on Breast Cancer Treatment Studies, Medical Imaging Techniques and Applications, Advanced Breast Cancer Therapies. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 14 companies, 4 NIH-funded awards (1996–2019).
- Most recent indexed publication: 2025 · Cancer epidemiology, biomarkers & prevention
- Top research focus: Breast Cancer Treatment Studies
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 84.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Sponsor: University of Washington
- Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
Sponsor: University of Washington
Industry payments
Updated 23 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GE HEALTHCAREProgram year20254 payments
- TOLMAR, INC.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
72.5%Aromatase Inhibitor47.7%Letrozole71%Anastrozole29%Part D<11 patientsKinase inhibitor17%Ibrance54%Tagrisso46%Part D<11 patients+ 1 more class in this area
Nervous system
19.6%Phenothiazine10.5%Prochlorperazine Maleate100%Part D≥11 patientsSNRI9.2%Duloxetine Hcl100%Part D<11 patientsMetabolism & gastrointestinal
7.8%Serotonin-3 Receptor Antagonist7.8%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
4 NIH research awards on record, funded 1996–2019 per NIH RePORTER. The latest:
- Advanced PET/CT Imaging for Improving Clinical Trials
University of Washington
FY2019$612,217U01CA148131 - Advanced PET/CT Imaging for Improving Clinical Trials
University of Washington
FY2018$606,598U01CA148131 - Advanced PET/CT Imaging for Improving Clinical Trials
University of Washington
FY2017$648,569U01CA148131
Congress activity
Updated 23 Oct 2026
70 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- The role of [18F]16α-fluoro-17β-fluoroestradiol (FES) PET in predicting response to endocrine therapy (ET) in advanced breast cancer.
ASCO Annual Meeting
ASCO2025Presenting author - 346P Randomized window trial comparing molecular impact of SERD vs AI vs tamoxifen in ILC (TBCRC 037)
ESMO Congress
ESMO2025Co-authorPoster
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing Subtypes.
Cancer epidemiology, biomarkers & prevention
Article2025 - Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast Cancer.
Cancer epidemiology, biomarkers & prevention
Article2024 - Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?
Clinical cancer research
Comment2023 - Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer.
Breast cancer research and treatment
Review2022
Most-cited works
by citation count (OpenAlex)- 01
- 02Pilot Feasibility Study of an Oncology Financial Navigation ProgramArticle218 citations2017
- 03
- 04Androgen Receptor Expression in Estrogen Receptor–Negative Breast CancerArticle206 citations2003
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/hannah-linden-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
fredhutch.org/en/people/l/hannah-m-linden.html
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fredhutch.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- MD
University of Massachusetts
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Editorial & leadership roles
journal and society appointments- Committee Member
SNMMI Committee on Outreach - Breast Cancer Imaging Working Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →snmmi.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Secondary affiliations
appointments beyond the home institution- Professor
Division of Hematology and Oncology, University of Washington School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- Associate Program Director
University of Washington/Fred Hutch Hematology-Oncology Fellowship
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope